Morning Break: Your Brain on Drugs; Mosquito Engineers; Floss Follies

— Health news and commentary from around the Web, gathered by the MedPage Today staff

MedpageToday

Raise your hand if you remember "This is your brain on drugs" and that it was followed by "Any questions?" and an image of an egg frying. Now that message has been tweaked as a real invitation to receive additional information. (The New York Times)

Cancer patients who run out of options in the U.S. are seeking cures in Cuba, where a compound called CimaVax has some promising early results -- so much so that a Roswell Park researcher is prepared an NDA on the drug, as Rob Waters reports in STAT.

The search for Zika treatments features a lot of old standards, reports Ellie Kincaid. (Nature Medicine)

But here's a novel way to attack a mosquito-borne illness like Zika -- build a better mosquito. (Reuters)

More on the to floss or not to floss question: CBC News offers a flossing defense from a dentist.

Surgery for a broken tibia gave one physician a new perspective on pain relief -- Rita Agarwal, MD, says the 0-10 pain scale is useless. (KevinMD)

The CDC is investigating a multistate Salmonella outbreak linked to alfalfa sprouts.

NPR reports the dilemma faced by pregnant and nursing women who find themselves unable to take medicines for chronic illnesses.

There may or may not be a shortage of doctors in the future, but either way graduates of international medical schools may have trouble finding residency slots. (Skeptical Scalpel)

And on the research beat: UC Berkeley bio engineers have developed dust mite size, implantable neural sensors that don't need batteries. The devices have a variety of potential uses ranging from biometric sensors to nerve stimulation. (University of California)

Results from early trials of a novel asthma drug, fevipiprant, are being touted as a "game changer" in consumer media. Hype?

Ohio officials say 24 people who attended a 2-day music festival were hospitalized with apparent drug overdoses. The cause, health officials say, was highly potent synthetic marijuana candies. (CNN)

A new judge will hear the challenge to the Anthem-Cigna deal, while the original judge -- Judge John Bates -- will hear challenges to Aetna's purchase of Humana. Bates had been assigned to both cases, but Judge Amy Berman Jackson in the D.C. circuit will take over the Anthem-Cigna case. (Reuters)

Morning Break is a daily guide to what's new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: MPT_editorial@everydayhealthinc.com.